Skip to main content
. Author manuscript; available in PMC: 2017 Dec 21.
Published in final edited form as: ACS Chem Neurosci. 2016 Oct 5;7(12):1706–1716. doi: 10.1021/acschemneuro.6b00230

Figure 6.

Figure 6

VU6004256 reduces hyperlocomotor activity in NR1 KD mice. Vehicle-treated NR1 KD mice showed excessive locomotor activity when compared to WT littermate controls. Pretreatment with VU6004256 (1–10 mg/kg) dose-dependently reduced locomotor activity in NR1 KD, but not in WT mice. (n = 7–9/treatment group, ** p < 0.01 vs NR1 KD vehicle, *** p < 0.001 vs WT vehicle, ANOVA followed by Bonferroni’s post hoc test).

HHS Vulnerability Disclosure